CorMedix Q2 2026 net income rises 31.1% to $26 million; revenue more than doubled to $101.9 million

• CorMedix posted Q2 2026 consolidated revenue of USD 101.9 million, up 156.57% from a year earlier.
• Net income rose to USD 26 million; diluted EPS slipped to USD 0.29.
• Adjusted EBITDA (non-GAAP) climbed to USD 58.7 million from USD 22.4 million.
• DefenCath net revenue was USD 66.1 million; the acquired Melinta portfolio added USD 35.8 million.
• FY 2026 consolidated revenue guidance held at USD 325-345 million; adjusted EBITDA (non-GAAP) outlook raised to USD 125-140 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130730PRIMZONEFULLFEED9809351) on August 13, 2026, and is solely responsible for the information contained therein.